Corpus Intelligence IC Memo — UTAH VALLEY SPECIALTY HOSPITAL 2026-04-26 08:01 UTC
IC Memo — UTAH VALLEY SPECIALTY HOSPITAL
Investment Committee Memorandum | UT | 40 beds | Grade C | EBITDA uplift $1.0M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

UTAH VALLEY SPECIALTY HOSPITAL

CCN 462005 | UTAH, UT | 40 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

UTAH VALLEY SPECIALTY HOSPITAL is a 40-bed safety-net/medicaid heavy in UTAH, UT with $14.1M in net patient revenue and a -8.8% operating margin. The hospital serves a payer mix of 28.0% Medicare, 26.4% Medicaid, and 45.6% commercial.

Thesis: Turnaround. Our ML models identify $1.0M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -8.8% to -1.5% (+737bps).

Net Revenue HCRIS$14.1M
Current EBITDA COMPUTED$-1.2M
Operating Margin COMPUTED-8.8%
Occupancy HCRIS57.1%
Revenue / Bed COMPUTED$353K
Net-to-Gross HCRIS41.9%
Distress Probability ML54.4%

2. Market Context & Competitive Position

59
UT Hospitals
8.0%
State Median Margin
25
Comparable Hospitals

UT has 59 Medicare-certified hospitals with a median operating margin of 8.0%. The target's margin of -8.8% places it below the state median. Among 25 size-comparable peers (20-80 beds), the median margin is 4.9%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (20-80), prioritizing same-state peers. 25 hospitals in the comp set.

HospitalStateBedsRevenueMargin
UTAH VALLEY SPECIALTY HOSPITAL (Target)UT40$14.1M-8.8%
CEDAR CITY HOSPITALUT48$136.8M31.4%
LONE PEAK HOSPITALUT61$133.1M25.2%
ALTA VIEW HOSPITALUT57$130.9M-0.6%
GUNNISON VALLEY HOSPITALUT25$130.4M-6.4%
LAYTON HOSPITALUT37$121.1M9.5%
PARK CITY HOSPITALUT37$120.8M13.7%
UINTAH BASIN MEDICAL CENTERUT33$119.9M1.8%
MOUNTAIN WEST MEDICAL CENTERUT36$96.1M38.5%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $1.0M (737bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$297K+210bp18mo
Cost to Collect4.5%2.5%$283K+200bp12mo
Denial Rate Reduction12.0%6.5%$280K+198bp12mo
A/R Days Reduction5200.0%3800.0%$172K+122bp9mo
Clean Claim Rate88.0%96.0%$10K+7bp6mo

5. EBITDA Bridge

Net Collection Rate
$297K
Cost to Collect
$283K
Denial Rate Reduction
$280K
A/R Days Reduction
$172K
Clean Claim Rate
$10K
Total EBITDA Uplift$1.0M
Current EBITDA$-1.2M
+ RCM Uplift+$1.0M
Pro Forma EBITDA$-207K
Current Margin-8.8%
Pro Forma Margin-1.5%
WC Released (1x)$542K

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-1.9M$2.2M0.00x-100.0%
Base (11x exit)10.0x11.0x$-1.9M$1.8M0.00x-100.0%
Bull Case9.0x11.0x$-1.7M$4.6M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-1.7M$4.5M0.00x-100.0%
Bear Case11.0x10.0x$-2.1M$-2.4M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-2.1M$-3.3M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
MediumElevated Medicaid exposure (26.4%)Medicaid reimburses below cost in most states. Mitigant: denial reduction lever has highest impact on Medicaid claims
HighElevated distress probabilityModel estimates 54.4% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 25 hospitals with 20-80 beds
  • Same-state prioritization (n=26)
  • Comp margins: P25=-12.4% / P50=4.9% / P75=15.6%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.